GHK-Cu Copper Peptide: What the Skin Studies Show and Why Injections Are Unproven

GHK-Cu is a small copper-binding peptide that occurs naturally in human blood and has been used in skin creams for decades. Its human evidence comes almost entirely from creams and gels, and even there it is thin and mixed: a few small trials, some positive, some negative, many run or written up by people with a commercial stake. We found no published human trial of injected GHK-Cu for anti-ageing, hair or healing. FDA has flagged injectable GHK-Cu for possible immune reactions and says human safety data are limited.³⁴⁵⁶¹¹

GHK-Cu has become one of the most talked-about peptides of 2026. Online posts promise scar-free, youthful skin, thicker hair and faster healing, and the peptide is increasingly sold for injection, alone or in blends such as "GLOW".¹⁵ This guide separates what has been tested from what is being sold. It gives no dosing information and recommends no products; it is not medical advice.

The short version

• What it is: GHK is a three-amino-acid peptide (glycine, histidine, lysine) first isolated from human blood in 1973. It binds copper, and the copper-bound form is called GHK-Cu or copper tripeptide-1.¹²
• Cream evidence is small and mixed. A 2026 systematic review found only two randomised controlled trials of GHK-Cu alone in aesthetic use, against 18 preclinical studies. One trial found less wrinkle depth; in the other, after laser treatment, objective skin measures were no better with GHK-Cu than without it.⁴⁷
• Wound results point both ways. A copper-peptide gel improved closure of diabetic foot ulcers in one trial, while a copper-peptide cream did no better than placebo for leg ulcers in another.⁸⁹
• Injections are untested. No published controlled trial has tested injected GHK-Cu on its own, and ClinicalTrials.gov listed no such trial as of 22 October 2026. The injected "hair" studies used mixtures of many ingredients with no control group.¹⁰¹⁴
• FDA's concern is about injection. FDA lists injectable GHK-Cu with a possible risk of immune reactions from aggregation and peptide-related impurities, and "limited data in humans" on safety. It was not among the peptides FDA's advisers reviewed in July 2026; FDA says they will discuss GHK-Cu at a meeting before the end of February 2027, and no date had been set by 22 October.¹¹¹²²²

What GHK-Cu is

GHK was described in 1973 by Pickart and Thaler, who found a small peptide in human serum that kept liver cells alive longer in the lab.¹ The peptide is glycyl-L-histidyl-L-lysine, and it is thought to act mainly as a complex with copper.² Reviews by Pickart's group report that GHK is present in plasma, saliva and urine and that levels fall with age.²

That "declines with age" claim is the starting point of most marketing: if levels fall, the argument goes, topping them up should restore youthful skin. The logic does not hold on its own. Many substances change with age without being the cause of ageing, and showing that adding a substance back helps requires controlled human trials. Our guide to correlation and causation explains why.

In the lab, GHK-Cu has a long list of reported effects on skin cells, including more collagen and changes in the activity of thousands of genes.² A 2026 review agreed that preclinical results consistently point to effects on tissue remodelling, inflammation and blood-vessel growth, but concluded that "the clinical evidence remains sparse".⁵ Results in cells and animals are a reason to run human trials, not a substitute for them; see human vs preclinical research.

What the skin and wound studies actually show

Cosmetic creams

Despite decades of use in skin-care products, controlled human data are scarce. A 2025 review of GHK as an anti-wrinkle ingredient described "a surprising absence of clinical studies" using GHK-Cu and its palmitoylated form, and noted that GHK is water-loving and unstable, which makes it hard to get through the outer layer of skin.³

A 2026 systematic review in Aesthetic Surgery Journal found 20 eligible studies of GHK-Cu used on its own in aesthetic medicine: 18 preclinical and only 2 randomised controlled trials.⁴ One trial reported less wrinkle volume and depth than the control. The other is the best-documented study in this field:

• After laser resurfacing: in a study in which 13 people completed follow-up, patients were randomly assigned skin-care regimens with or without GHK-Cu after CO2 laser treatment around the mouth. "Objective evaluation found no significant improvement in wrinkles or overall skin quality." Patients using the copper peptide were more satisfied with how their skin looked.⁷

Other recent reviews reach the same conclusion. One 2026 review called GHK-Cu "a promising but unproven therapeutic cargo rather than a clinically validated regenerative drug", and noted that a small 2026 randomised, double-blind, split-face eyebrow study reported positive results without defining exactly what form of copper peptide was applied.⁵

Wound healing

The strongest-looking human results are in wounds, and they conflict:

• Diabetic foot ulcers: in a multicentre, randomised, evaluator-blinded, placebo-controlled trial, a GHK-Cu gel added to intensive standard wound care increased closure of plantar ulcers (median 98.5% of the area, compared with 60.8% with the inactive gel).⁹ The abstract does not give the number of patients, and the result applies to that gel in that setting.
• Venous leg ulcers: in a randomised, evaluator-blinded trial with 86 evaluable patients, a copper-peptide cream did no better than placebo, while an established antibacterial cream did better than both.⁸

Neither study tested a cosmetic serum, and neither tested injection. A ClinicalTrials.gov record shows a company-sponsored phase 2 trial of a topical GHK-Cu gel on standardised skin wounds in healthy adults (NCT07437586). It was recruiting in 2026 and has no results yet.¹⁴

Who wrote the evidence

A 2026 systematic review counted roughly 35% of the primary GHK-Cu papers in its search window as including Loren Pickart or Anna Margolina of Skin Biology, a skin-care company.⁶ The authors called this work "scientifically substantive" but said the concentration of authorship "limits the independence of the evidence base". Several of the broadest claims for GHK, such as that it can reset thousands of genes "to a healthier state", come from reviews written by this group.²

Commercial links are common elsewhere too. In a 2024 open-label dandruff study of a scalp scrub and a serum containing copper tripeptide-1 along with several other ingredients, one author was employed by the products' manufacturer and the others worked for or were paid by the research company that ran the study.¹⁶ A study with no control group, several active ingredients and a manufacturer on the author list cannot tell you what GHK-Cu itself does.

Injections: what has and has not been studied

The current trend is to inject GHK-Cu for anti-ageing, hair or "recovery". The evidence for that route is close to nothing.

• No trial of GHK-Cu alone. We found no published randomised or controlled trial of injected GHK-Cu in people for any purpose, and ClinicalTrials.gov listed none on 22 October 2026.¹⁴ A 2026 review of unapproved peptides used in sports medicine, including GHK-Cu, said "rigorous human safety data are scarce, and there is potential for serious harm to patients".¹⁷
• Hair studies used mixtures. The injected hair studies people cite tested cocktails. In one open-label study of 1,000 patients, the scalp injection contained four growth factors, thymosin β4 and copper tripeptide-1, and there was no control group.¹⁰ Any effect cannot be traced to GHK-Cu. Our guide to peptides for hair growth covers the treatments with stronger evidence.
• Cream data do not transfer. A cream studied on intact or laser-treated skin says nothing about what happens when the same molecule, in an unknown formulation, is injected repeatedly. A 2026 review stressed that the form of copper in a product, how much "labile" (loosely bound) copper it contains and how it breaks down all vary with formulation and can change toxicity.⁵

For a blend that includes GHK-Cu, see our explainer on GLOW and KLOW peptide stacks.

Safety: what we know and what we do not

On the skin, copper-peptide cosmetics have been on sale for decades. Their safety evidence is still limited: the trials were small, short and focused on effectiveness, and cosmetics are not pre-approved by FDA.⁷⁸¹³

By injection, the main questions are unanswered:

• Immune reactions. FDA says compounded injectable GHK-Cu "may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities", and that "there are limited data in humans to inform safety-related considerations".¹¹
• Product quality. Injectable GHK-Cu bought online is typically labelled "research use only". That label means the product has not been made or checked to medicine standards for sterility, endotoxin or content. See what "research use only" really means and our guide to peptide impurities.
• Long-term effects. No study has followed people injecting GHK-Cu on its own over months or years. The one large injected study used a mixture, had no control group and said only that treatment was "well tolerated".¹⁰ Reports of side effects from online peptides are covered in our peptide side effects explainer.

If you have had a reaction to any peptide product, tell a doctor and report it to FDA's MedWatch programme or your national regulator.

Regulatory status, as of 22 October 2026

As a cosmetic ingredient

GHK-Cu, listed on labels as copper tripeptide-1, is widely used in cosmetics. FDA explains that cosmetic products and ingredients generally do not need its approval before sale, apart from colour additives.¹³ Some media coverage has described GHK-Cu as an "FDA-approved" cosmetic ingredient; that is not how cosmetics are regulated.¹⁵ FDA also says that intended use decides whether a product is a cosmetic or a drug: claims that a product will, for example, "restore hair growth" can make it a drug that needs approval.¹³

As an injectable

GHK-Cu is not an FDA-approved medicine. FDA's page on bulk substances that may present significant safety risks lists "GHK-Cu (for injectable routes of administration)" among substances that were in category 2 of its compounding policy and whose nominations were later withdrawn by the nominators.¹¹ It was not one of the seven peptides FDA's Pharmacy Compounding Advisory Committee reviewed on 23–24 July 2026 (BPC-157, KPV, TB-500, MOTS-c, emideltide, Semax and Epitalon).¹² FDA says its advisers will discuss GHK-Cu at a meeting before the end of February 2027; no date had been set by 22 October.²²

For a substance with no official monograph that is not part of an approved drug, the law allows compounding only if it is on the 503A bulks list. While that list is being built, FDA does not intend to take action over substances in category 1 of its interim policy; for substances outside category 1, it says it "would consider taking action" against compounders.¹⁸ Injectable GHK-Cu is not in category 1. GHK-Cu for other routes, such as on the skin, was added back to category 1 in May 2026, after one nominator said it had withdrawn only the injectable route.¹¹²¹ On 14 October 2026, FDA sent an "Interim Access Policy for Compounding Using Certain Peptides" to the White House for review; it was still under review on 22 October. Reporting named BPC-157, and no list has been published, so it is not known whether GHK-Cu is included.¹⁹ Our explainers on the HHS peptide plan and on compounded peptides give the background.

How to read the GHK-Cu trend

When you see a GHK-Cu claim, four questions sort most of it out:

1. Which route was studied? Almost all human data are for creams and gels. A cream result is not evidence for an injection.
2. Was GHK-Cu the only active ingredient? A mixture of growth factors, peptides and other ingredients cannot show what GHK-Cu does on its own.¹⁰¹⁶
3. Was there a control group, and was the outcome measured objectively? In the post-laser study, patients using GHK-Cu rated their skin as better, but objective measures showed no difference between the groups.⁷
4. Who ran and wrote up the study? A large share of the literature comes from one company-linked group, and some recent studies list the product's manufacturer among the authors.⁶¹⁶

Our guide to verifying peptide claims on social media applies the same questions more widely, and the GHK-Cu profile summarises each human study.

Frequently asked questions

Does GHK-Cu work for wrinkles?

Possibly a little, in some formulations, but the evidence is weak. A 2026 systematic review found only two randomised trials of GHK-Cu alone in aesthetic use, with one positive and one negative on objective measures.⁴⁷ A dermatologist can explain the options with stronger evidence.

Is injecting GHK-Cu safe?

Nobody knows. No published trial has tested injected GHK-Cu on its own, and FDA has flagged possible immune reactions and limited human safety data for the injectable form.¹¹¹⁴ Products sold online for injection are not made or checked to medicine standards for sterility or contents.

Does GHK-Cu help hair grow?

The evidence is thin. One small 2026 trial in 18 people found more and thicker eyebrow hairs on the side treated with a GHK-Cu serum than on the side given a dummy serum. It studied eyebrows, not hair loss, and did not report the product's exact chemistry.²⁰ The injected hair studies tested mixtures of many ingredients with no control group.¹⁰¹⁶ Claims that a product restores hair growth make it a drug under US law, which requires approval.¹³

Is GHK-Cu the same as the "copper peptide" in my serum?

Usually yes: copper tripeptide-1 is the label name for GHK-Cu. But the amount, form and stability of the copper peptide vary between products, and a product containing the ingredient is not the product that was tested in a study.⁵

Is GHK-Cu banned?

Not as a cosmetic ingredient. Injectable GHK-Cu is not an approved medicine and is not in category 1 of FDA's interim compounding policy. GHK-Cu for other routes is in category 1, and FDA's advisers are due to discuss it before the end of February 2027.¹¹²¹²²